Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitorOngoingOpen NCT06996093 on ClinicalTrials.gov ↗
Population
Loading…
Intervention
Loading…
Comparator
Loading…
Loading…